Sandoz Group AG

Sandoz Group AG is a Swiss-based pharmaceutical company recognized as a global leader in the development and manufacturing of generic medicines and biosimilars. The company’s main purpose is to enhance worldwide access to high-quality, affordable pharmaceuticals, playing a pivotal role in both healthcare systems and patient care. Sandoz serves a broad array of healthcare providers and patients by supplying a comprehensive range of therapies, from everyday generic drugs to advanced biological medicines, enabling significant cost savings for public and private healthcare systems. With a substantial international footprint, Sandoz impacts critical sectors such as hospitals, pharmacies, and outpatient care, distributing treatments in more than 100 countries. The company's heritage dates back to 1886 and includes a long-standing history of innovation, particularly in areas like organ transplantation and neuroscience. After spinning off from Novartis in 2023, Sandoz Group AG reaffirmed its commitment to pioneering access to medicines by leveraging its expertise in both small molecule generics and complex biosimilars. Sandoz continues to play an essential role in expanding healthcare access globally and supporting sustainable medical solutions through its extensive product portfolio.